Clinical trials recruiting for EGFR Positive Non-small Cell Lung Cancer
3
Recruiting trials
1
US states with sites
3
Countries
0%
Accept healthy volunteers
Phase breakdown
Phase 2 1Not applicable 2
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Massachusetts | 1 |
Top cities
Self-screener
Recruiting trials
- Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
- Osimertinib for Advanced EGFR-positive NSCLC Patients
- Patient-centered, Optimal Integration of Survivorship and Palliative Care
Related conditions
Trials recruiting for EGFR Positive Non-small Cell Lung Cancer often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Targeted Therapy 8Survivorship 12Stage IV Non-small Cell Lung Cancer 7Palliative Care 5Nonsmall Cell Lung Cancer 7Non-small cell lung cancer 507MET Amplification 4ALK-positive Non-small Cell Lung Cancer 6
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for EGFR Positive Non-small Cell Lung Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.